Renal Cell Carcinoma
From the Journals
Cancer rates on the rise in adolescents and young adults
From the Journals
Fear of recurrence highly prevalent in RCC survivors
About 55% of survivors surveyed expressed fear of renal cell carcinoma recurrence.
Conference Coverage
Risk factors for severe immune-related AEs identified
A nationwide cohort study of more than 14,000 patients finds combination immune checkpoint inhibitor therapy, younger age, and a lung cancer...
Clinical Insights
Using telehealth to deliver palliative care to cancer patients
Dr. Alan Lyss discusses the use of telehealth for palliative cancer care, including results from the REACH PC trial.
From the Journals
Pembrolizumab plus axitinib continues to outshine sunitinib for advanced RCC
The combination produced a survival benefit in the overall population but not among patients with favorable-risk disease.
From the Journals
No benefit with adjuvant sorafenib in intermediate-/high-risk RCC
Survival was similar with adjuvant sorafenib and placebo.
From the Journals
Real-world results with checkpoint inhibitors found inferior to trial results
Data suggest real-world survival is worse than survival in clinical trials.
Conference Coverage
Lower BP and better tumor control with drug combo?
Feature
Are oncologists ready to confront a second wave of COVID-19?
Conference Coverage
Durable efficacy with MK-6482 in VHL-associated RCC
MK-6482 produced responses in patients with Von Hippel-Lindau disease-associated renal cell carcinoma and non-renal lesions.
Conference Coverage
Clinical factors and treatment tied to COVID-19 mortality in cancer patients
Analyses of CCC19 data revealed factors linked to mortality in patients with COVID-19 and cancer.